Teva has received approval to market in Europe: Ajovy a treatment for migraine

Teva has received approval from the European Council to market Ajovy, a migraine-prevention shot in adults with at least four migraine days a month. Agovy is a CGRP blocker, a neurotransmitter responsible for transmitting messages in different parts of the body and involved in the biological processes that cause migraine.
Agovi of Teva competes with two other drugs from this family: Aimovig of Amgen and Emgality of Eli Lilly. Teva's drug is the only one approved and given once a quarter and once a month.
The European Council's decision is valid for all 28 EU member states, in addition to Iceland, Norway and Liechtenstein. Migraine drugs are designed to treat 50 million patients in EU countries.
Teva received approval to market Ajobi in the United States in September 2018, and holds 19% of the prescription for migraine drugs and 30% of the prescriptions for new patients Teva estimates that Agobe's US sales will grow from $ 6 million in 2018 To $ 150 million in 2019.